DRIVIN G ROWTH - Dr. Reddy's

56
management discussion
and analysis
CHART C
LAUNCH OF AURIGENE
DISCOVERY TECHNOLOGIES LTD.
IN ORDER TO TRANSFORM itself
into a discovery-led global pharmaceutical
company, the Company promoted as a
wholly owned subsidiary, Aurigene
Discovery Technologies Ltd. (Aurigene) — a
post-genomic discovery services company.
Investment in this project in 2001-02
amounted to Rs. 111 million.
Under the leadership of Dr. Norton Peet,
Aurigene will focus on building skills in
automated medicinal chemistry, structural
biology and structure based drug design.
The idea is to provide products and services
that eliminate bottlenecks in discovery
process. The initial focus of Aurigene will be
to establish alliances with pharmaceutical
companies for chemistry and protein
services and other related drug discovery
activities.
Aurigene will have a research facility at
Bangalore, which is expected to be partially
operational by September 2002, and go
fully on stream by December 2002. The
Bangalore facility is expected to have over
100 scientists in the very first year of
operation. Aurigene will also have a
business development centre and a highly
specialised research laboratory in Boston,
USA — the new global hub of discovery
research, along with New Jersey.
With the setting up of Aurigene, Dr.
Reddy’s will have direct access to discovery
research out of three dedicated facilities:
(i) Dr. Reddy’s Research Foundation (DRF)
located at Hyderabad, (ii) Reddy US
Therapeutics Inc. (RUSTI) at Atlanta, and
DR. REDDY’S LABORATORIES LTD. | MANAGEMENT DISCUSSION AND ANALYSIS | ANNUAL REPORT 2001-2002